Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Stock Position Decreased by Rhenman & Partners Asset Management AB

Rhenman & Partners Asset Management AB lowered its holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 24.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 114,000 shares of the company’s stock after selling 36,000 shares during the period. Rhenman & Partners Asset Management AB’s holdings in Dianthus Therapeutics were worth $2,485,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of DNTH. State Street Corp increased its position in Dianthus Therapeutics by 101.4% in the third quarter. State Street Corp now owns 821,131 shares of the company’s stock worth $22,483,000 after buying an additional 413,425 shares during the period. Janus Henderson Group PLC increased its stake in shares of Dianthus Therapeutics by 40.5% in the third quarter. Janus Henderson Group PLC now owns 949,334 shares of the company’s stock valued at $25,936,000 after purchasing an additional 273,670 shares during the period. Point72 Asset Management L.P. raised its holdings in shares of Dianthus Therapeutics by 151.3% during the third quarter. Point72 Asset Management L.P. now owns 437,700 shares of the company’s stock valued at $11,984,000 after buying an additional 263,500 shares during the last quarter. Alliancebernstein L.P. boosted its position in shares of Dianthus Therapeutics by 13.4% during the fourth quarter. Alliancebernstein L.P. now owns 1,159,776 shares of the company’s stock worth $25,283,000 after buying an additional 136,633 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its holdings in Dianthus Therapeutics by 142.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 165,929 shares of the company’s stock worth $4,543,000 after buying an additional 97,362 shares in the last quarter. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on DNTH shares. Wedbush reiterated an “outperform” rating and set a $36.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. TD Cowen started coverage on shares of Dianthus Therapeutics in a research report on Friday, December 20th. They issued a “buy” rating for the company. Guggenheim reissued a “buy” rating and set a $84.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Finally, Raymond James raised Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $54.33.

Dianthus Therapeutics Stock Performance

NASDAQ DNTH opened at $16.12 on Friday. Dianthus Therapeutics, Inc. has a 1 year low of $14.78 and a 1 year high of $32.27. The business’s fifty day moving average is $21.48 and its two-hundred day moving average is $23.92. The stock has a market capitalization of $517.86 million, a P/E ratio of -6.45 and a beta of 1.62.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The company had revenue of $1.33 million for the quarter, compared to analyst estimates of $1.40 million. On average, research analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.